Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 December 2019 | Story Valentino Ndaba | Photo Stephen Collett
Justice read more
Social justice is the promotion of just societies and treatment of individuals and communities based on the belief that we each possess an innate human dignity.

The power of research lies in the possibility to move from theory to practical outcomes that can change society for the better in some way. In essence, scholars have the ability to create the future in collaboration with government and civil society. At a recent international colloquium hosted by the University of the Free State (UFS) South African Research Chairs Initiative (SARChI) programme, researchers deliberated on social justice issues and possible resolutions.

Delegates from institutions across the UK, Zimbabwe, and Sweden presented findings from studies conducted around the world under the theme ‘Making Epistemic Justice: An international colloquium on narrative capabilities and participatory research’. The UFS SARChI Chair in Higher Education and Human Development Research Programme, under the leadership of Professor Melanie Walker hosted the colloquium from 21-22 November in Bloemfontein.

The importance of psychological liberation

In her welcoming address, Prof Walker quoted the late Black Consciousness activist, Steve Biko, who anticipated many of the current debates on epistemic power and exclusions when he wrote that “the most potent weapon in the hands of the oppressor is the mind of the oppressed”.

Prof Walker reiterated that epistemic justice matters, as affirmed by Kenyan writer, Ngũgĩ wa Thiong’o who in 1981 stated that, “colonialism imposed its control over social production of wealth through military conquest and subsequent political dictatorships. But its most important area of domination was the mental universe of the colonised, the control through culture, how people perceive themselves, and their relationship to the world”.

The relationship between storytelling and social justice

Dr Holly Henderson from the University of Nottingham in the UK was the first speaker to make a presentation, titled ‘Resisting the narrative conclusion in educational research’. According to Henderson, storytelling is an essential part of the long road to social justice.  

Henderson’s keen interest in the complexity of the narrative developed when she started working in further education many years ago. A significant part of her research focuses on the concept of ‘possible self’ which requires the art of storytelling in order to come to life. A study she conducted on university students delved deeper into this concept and found that environment plays a major role in the way individuals perceive the future. 

“The more detailed you imagine something, the more likely you are to achieve it,” said Henderson. However, the correct structures enable the future to be imagined. Hence, curriculum decolonisation, equal access to quality education, and social justice become all the more important in achieving future success among students globally.
 
The art of activism and advocacy 

The joint work of Dr Faith Mkwananzi from the UFS and Dr Tendayi Marovah from the Midlands State University in Zimbabwe looked at street art, otherwise known as graffiti, as a way to foster epistemic justice and collective capabilities among marginalised youth. 

According to Marovah, storytelling using art gives a voice to the voiceless and assigns dignity to the excluded. “Narrative offers an opportunity in which the unheard and unseen are heard and seen.”

Delegates of the colloquium unanimously agreed that researchers are in the business of providing much-needed direction on how to stop discrimination, challenging unjust government policies and the abuse of power, promoting peace instead of violence, eradicating poverty, opening access to quality education among other social justice issues. Therefore unity in research diversity provides fertile ground for manifesting social justice.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept